Der Radiologe

, Volume 54, Issue 2, pp 140–144 | Cite as

Chirurgische Optionen bei „cancer of unknown primary“ (CUP)

Leitthema

Zusammenfassung

Hintergrund

„Cancer of unknown primary“ (CUP) stellt eine im klinischen Alltag häufig auftretende heterogene Gruppe an Tumorerkrankungen dar, die bisher mit einer äußerst schlechten Prognose für die betroffenen Patienten einhergeht. Aufgrund der zunehmend besseren diagnostischen Möglichkeiten lassen sich Subgruppen von Patienten mit unterschiedlicher klinischer Prognose identifizieren. Neue, an die identifizierten Subgruppen angepasste Therapien, spielen zunehmend eine entscheidende Rolle.

Zielsetzung

In diesem Review sollen die Rolle der Chirurgie und die chirurgischen Optionen in der Therapie von CUP-Patienten erläutert werden.

Ergebnisse

Für die Therapie des CUP ist eine Eingruppierung der Patienten in unterschiedliche Subgruppen von Bedeutung, um die Patienten mit einer guten Prognose identifizieren zu können. Eine chirurgische Resektion der CUP-Metastasen stellt für 1) Frauen mit papillärer Peritonealkarzinose, 2) Frauen mit axillären Lymphknotenmetastasen eines Adenokarzinoms, 3) Patienten mit zervikalen Lymphknotenmetastasen eines Plattenepithelkarzinoms, 4) Patienten mit inguinalen Lymphknotenmetastasen, 5) Patienten mit mediastinalen/retroperitonealen Metastasen entlang der Mittellinie (extragonadale Keimzelltumoren) und für 6) Patienten mit lokalisierten, resezierbaren Metastasen eine lebensverlängernde Therapieoption dar.

Schlussfolgerung

Zusammen mit einer dem vermutlichen Primärtumor angepassten multimodalen Therapie stellt die Resektion von Metastasen bei verschiedenen Subgruppen des CUP eine wichtige Therapieoption dar.

Schlüsselwörter

Adenokarzinome Plattenepithelkarzinome Prognose Peritonealkarzinose Lymphknotenmetastasen 

Surgical options in cancer of unknown primary (CUP)

Abstract

Background

Cancer of unknown primary site (CUP) comprises a relatively frequently occurring group of heterogeneous malignant tumors in the clinical routine, which currently has an abysmal prognosis for affected patients. Based on the improved diagnostic tools it is now possible to identify subgroups of patients with different clinical prognoses. New therapies adapted to these identified subgroups are becoming increasingly more relevant.

Aim

This review aims to evaluate the role of surgery and different surgical options in the therapy of patients with CUP.

Results

For the treatment of patients with CUP it is important to identify subgroups of patients with a better prognosis. Surgical resection of CUP metastasis is a therapy option leading to a prolonged survival in (1) women with papillary peritoneal adenocarcinomatosis, (2) women with axillary lymph node metastasis of adenocarcinoma, (3) patients with cervical lymph node metastasis of squamous cell carcinoma, (4) patients with inguinal lymph node metastasis, (5) patients with poorly differentiated carcinomas with midline distribution (e.g. extragonadal germ cell syndrome) and (6) patients with small resectable tumors.

Conclusion

Surgery is an important therapy option in different subgroups of patients with CUP. Together with multimodal therapy, adjusted according to the identified most likely origin of the primary tumor, it is possible to prolong patient survival.

Keywords

Adenocarcinomas Squamous cell carcinomas Prognosis Peritoneal carcinomatosis Lymph node metastasis 

Literatur

  1. 1.
    Albany C, Einhorn LH (2013) Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol 25:261–265PubMedGoogle Scholar
  2. 2.
    Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955PubMedCrossRefGoogle Scholar
  3. 3.
    Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43PubMedCrossRefGoogle Scholar
  4. 4.
    Ben-Baruch G, Sivan E, Moran O et al (1996) Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III–IV ovarian papillary serous carcinoma. Gynecol Oncol 60:393–396PubMedCrossRefGoogle Scholar
  5. 5.
    Chen AM, Farwell DG, Lau DH et al (2011) Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys 81:346–352PubMedCrossRefGoogle Scholar
  6. 6.
    Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030–1047PubMedCrossRefGoogle Scholar
  7. 7.
    Dennis JL, Oien KA (2005) Hunting the primary: novel strategies for defining the origin of tumours. J Pathol 205:236–247PubMedCrossRefGoogle Scholar
  8. 8.
    Deraco M, Virzi S, Iusco DR et al (2012) Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG 119:800–809PubMedCrossRefGoogle Scholar
  9. 9.
    Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150PubMedCrossRefGoogle Scholar
  10. 10.
    Fizazi K, Greco FA, Pavlidis N et al (2011) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi64–vi68PubMedCrossRefGoogle Scholar
  11. 11.
    Grau C, Johansen LV, Jakobsen J et al (2000) Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 55:121–129PubMedCrossRefGoogle Scholar
  12. 12.
    Guarischi A, Keane TJ, Elhakim T (1987) Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 59:572–577PubMedCrossRefGoogle Scholar
  13. 13.
    Hainsworth JD, Rubin MS, Spigel DR et al (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31:217–223PubMedCrossRefGoogle Scholar
  14. 14.
    Hemminki K, Bevier M, Hemminki A et al (2012) Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 23:1854–1863PubMedCrossRefGoogle Scholar
  15. 15.
    Kennedy AW, Markman M, Webster KD et al (1998) Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol 71:288–290PubMedCrossRefGoogle Scholar
  16. 16.
    Kesler KA, Rieger KM, Hammoud ZT et al (2008) A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 85:371–378PubMedCrossRefGoogle Scholar
  17. 17.
    Killackey MA, Davis AR (1993) Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 51:171–174PubMedCrossRefGoogle Scholar
  18. 18.
    Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007PubMedGoogle Scholar
  19. 19.
    Matsuyama S, Nakafusa Y, Tanaka M et al (2006) Iliac lymph node metastasis of an unknown primary tumor: report of a case. Surg Today 36:655–658PubMedCrossRefGoogle Scholar
  20. 20.
    Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRefGoogle Scholar
  21. 21.
    Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379:1428–1435PubMedCrossRefGoogle Scholar
  22. 22.
    Pavlidis N, Pentheroudakis G, Plataniotis G (2009) Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 11:340–348PubMedCrossRefGoogle Scholar
  23. 23.
    Pentheroudakis G, Briasoulis E, Karavassilis V et al (2005) Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective? Acta Oncol 44:155–160PubMedCrossRefGoogle Scholar
  24. 24.
    Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418–425PubMedCrossRefGoogle Scholar
  25. 25.
    Pentheroudakis G, Lazaridis G, Pavlidis N (2010) Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 119:1–11PubMedCrossRefGoogle Scholar
  26. 26.
    Pentheroudakis G, Pavlidis N (2010) Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 75:27–42PubMedCrossRefGoogle Scholar
  27. 27.
    Pentheroudakis G, Stoyianni A, Pavlidis N (2011) Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis? Cancer Treat Rev 37:120–126PubMedCrossRefGoogle Scholar
  28. 28.
    Piver MS, Eltabbakh GH, Hempling RE et al (1997) Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol 67:141–146PubMedCrossRefGoogle Scholar
  29. 29.
    Sher DJ, Balboni TA, Haddad RI et al (2011) Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys 80:1405–1411PubMedCrossRefGoogle Scholar
  30. 30.
    Strnad CM, Grosh WW, Baxter J et al (1989) Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 111:213–217PubMedCrossRefGoogle Scholar
  31. 31.
    Taus P, Petru E, Gucer F et al (1997) Primary serous papillary carcinoma of the peritoneum: a report of 18 patients. Eur J Gynaecol Oncol 18:171–172PubMedGoogle Scholar
  32. 32.
    Vuky J, Bains M, Bacik J et al (2001) Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 19:682–688PubMedGoogle Scholar
  33. 33.
    Zivanovic O, Eisenhauer EL, Zhou Q et al (2008) The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 108:287–292PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Klinik für Allgemein-, Viszeral- und TransplantationschirurgieUniversitätklinikum HeidelbergHeidelbergDeutschland

Personalised recommendations